Aquestive Therapeutics (NASDAQ: AQST)
Aquestive Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Aquestive Therapeutics Company Info
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
News & Analysis
Why Aquestive Therapeutics Dived by 29% Today
A decision on a crucial regulatory filing is being delayed indefinitely.
These 2 Pharma Stocks Could Be Top Stocks in 2020
These pharma stocks are undervalued, and could be solid picks over the long term.
Valuation
Earnings Transcripts
Aquestive Therapeutics, Inc. (AQST) Q2 2022 Earnings Call Transcript
AQST earnings call for the period ending June 30, 2022.
Aquestive Therapeutics, Inc. (AQST) Q1 2022 Earnings Call Transcript
AQST earnings call for the period ending March 31, 2022.
Aquestive Therapeutics, Inc. (AQST) Q4 2021 Earnings Call Transcript
AQST earnings call for the period ending December 31, 2021.
Aquestive Therapeutics, Inc. (AQST) Q3 2021 Earnings Call Transcript
AQST earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.